Skip to content
lifestyle.cosmeticsurgeryinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BeyondSpring, Inc.
BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
November 13, 2026
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
September 29, 2026
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
August 14, 2026
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
June 4, 2026
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
June 2, 2026
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
May 18, 2026
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
February 12, 2026